BC
ROIV icon

Bridgefront Capital’s Roivant Sciences ROIV Stock Holding History

Bridgefront Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$699K Buy
19,746
+8,537
+76% +$252K 0.18% 190
2026
Q1 		$310K Buy
+11,209
New +$288K 0.08% 386
2024
Q4 		– Sell
-32,444
Closed -$374K – 756
2024
Q3 		$374K Buy
+32,444
New +$369K 0.14% 263

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Bridgefront Capital's ROIV Position: Q2 2026 in Review

Bridgefront Capital increased its Roivant Sciences (ROIV) stake by 76% in Q2 2026, buying an estimated $252K and bringing the position to 19,746 shares worth $699K. The position accounts for 0.18% of the portfolio, ranked #190.

Bridgefront Capital first reported a position in ROIV in Q3 2024 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Bridgefront Capital held 19,746 shares of Roivant Sciences worth $699K as of Q2 2026.
  • Bridgefront Capital bought 8,537 Roivant Sciences shares in Q2 2026, an estimated $252K.
  • Roivant Sciences made up 0.18% of Bridgefront Capital's portfolio in Q2 2026, its #190 holding.
  • Bridgefront Capital first reported a position in Roivant Sciences in Q3 2024 and has held it in 3 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.